Navigation Links
Women in technology confab comes to Wisconsin

Farm in New Jersy, which runs a children's summer camp. This year's may be in a more adult location, but Ryan said she's going for the same mellow atmosphere.

"I remember having one conversation under an oak tree with a couple of women between sessions where I actually helped one of them map out her marketing plan for a Web site," Drucker-Holberton said. "And we did it in thirty minutes.......

Full article >>>
'"/>

Source:wistechnology.com By Jason Stitt 05/18/05


Page: 1 2

Related biology technology :

1. Womens entrepreneurial event set for May 21
2. Women entrepreneurs reach for $1M level
3. Women and Capital: Two words that dont always marry
4. Women entrepreneurs are finding ways to succeed in Wisconsin and beyond
5. Unique profiles, anecdotes increase Millionaire Womens net worth
6. List of Key Midwest Biotech Women Grows
7. Women in Midwest IT Have to Fight, Work Harder
8. GE Launches Womens Health Initiative
9. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. GOP, Dems split over funding of state technology projects
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Women technology confab comes Wisconsin

Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2